approval
saveKESIMPTA (OFATUMUMAB) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 1, 2026 · 187d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 18, 2025 · 413d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 12, 2024 · 906d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalSep 2, 2022 · 1494d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 20, 2020 · 2237d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalAug 30, 2016 · 3688d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalJan 19, 2016 · 3912d ago
- approvalKESIMPTA (OFATUMUMAB) — FDA approvalApr 17, 2014 · 4554d ago
same company · ±60 days · 6
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalFeb 27, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalFeb 27, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalFeb 27, 2024
- approvaldabrafenib mesylate ODT: TAFINLAR (DABRAFENIB MESYLATE) — FDA approvalFeb 27, 2024
- approvalImatinib Mesylate Shilpa: GLEEVEC (IMATINIB MESYLATE) — FDA approvalMar 1, 2024
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalNov 21, 2023
comments(0)
5-min edit window · permanent after that